Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Industry, Sector and Symbol
Industry Drug Delivery
Sub-IndustryN/A
SectorMedical
Phone+44-1283-495010
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees849
OptionableNot Optionable
Clinigen Group (LON:CLIN) Frequently Asked Questions
What is Clinigen Group's stock symbol?
Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."
How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group?
Clinigen Group declared a dividend on Thursday, September 27th. Stockholders of record on Thursday, November 8th will be paid a dividend of GBX 3.84 per share on Friday, November 30th. This represents a dividend yield of 0.46%. The ex-dividend date is Thursday, November 8th. This is a positive change from Clinigen Group's previous dividend of $1.76. The official announcement can be accessed at this link. View Clinigen Group's Dividend History.
How were Clinigen Group's earnings last quarter?
Clinigen Group PLC (LON:CLIN) posted its quarterly earnings results on Tuesday, February, 27th. The company reported $21.20 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $20.30 by $0.90. The business had revenue of $167.80 million for the quarter. View Clinigen Group's Earnings History.
What price target have analysts set for CLIN?
5 equities research analysts have issued 1-year target prices for Clinigen Group's shares. Their predictions range from GBX 1,160 to GBX 1,470. On average, they expect Clinigen Group's share price to reach GBX 1,273 in the next year. This suggests a possible upside of 43.7% from the stock's current price. View Analyst Price Targets for Clinigen Group.
What is the consensus analysts' recommendation for Clinigen Group?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clinigen Group.
Has Clinigen Group been receiving favorable news coverage?
Media coverage about CLIN stock has been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Clinigen Group earned a news impact score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Clinigen Group's key competitors?
Some companies that are related to Clinigen Group include 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abaxis (ABAX), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acreage (ACRGF), Activecare (ACAR), Advanced Accelerator Application (AAAP), Advanced Medical Solutions (AMS), Advanced Oncotherapy (AVO), AEGON (AGN), Airware Labs (AIRW) and Akers Biosciences (AKR).
Who are Clinigen Group's key executives?
Clinigen Group's management team includes the folowing people:
- Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 51)
- Mr. Martin Abell, CFO & Director
- Ms. Debra Ainge, Chief Operating Officer
- Matt Parrish, Head of Investor Relations
- Mr. David Bryant, Director of Corp. Devel.
How do I buy shares of Clinigen Group?
Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Clinigen Group's stock price today?
One share of CLIN stock can currently be purchased for approximately GBX 886.
What is Clinigen Group's official website?
How can I contact Clinigen Group?
Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010.
MarketBeat Community Rating for Clinigen Group (LON CLIN)
MarketBeat's community ratings are surveys of what our community members think about Clinigen Group and other stocks. Vote "Outperform" if you believe CLIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
